Use

This test assists in the clinical management of patients with metastatic breast cancer by identifying tumors with evolving resistance to endocrine therapy. It helps in stratifying the prognosis of metastatic breast cancer. The test evaluates somatic mutations within the ESR1 gene to provide insights into the potential mechanisms leading to resistance against endocrine treatments such as selective estrogen receptor modulators and degraders, and aromatase inhibitors. By identifying mutations in the ligand-binding domain of ESR1, the assay aids in determining patient eligibility for targeted therapies like elacestrant (Orserdu), which is indicated for specific patient groups with ESR1 mutations.